INTRODUCTION {#s1}
============

Endometriosis is a common condition in premenopausal women characterized by chronic pelvic inflammation causing pain and subfertility ([@DDU516C1]), and has an estimated heritability of 51% ([@DDU516C2]). The International Endogene Consortium (IEC) performed the largest endometriosis GWAS to date in 3194 surgically confirmed cases (including 1364 moderate--severe---Stage B---cases) and 7060 controls of European ancestry, with replication in a further 2392 cases and 2271 controls ([@DDU516C3]). One genome-wide significant locus was observed in an intergenic region on chromosome 7p15.2 (rs12700667), primarily associated with Stage B disease (*P* = 1.5 × 10^−9^, OR = 1.38, 95% CI 1.24--1.53). A second locus near *WNT4* (rs7521902) was found after meta-analysis with published results from a Japanese GWAS of 1423 cases and 1318 controls ([@DDU516C4]); a genome-wide meta-analysis confirmed the two loci and found a further five ([@DDU516C5]).

Rs12700667 on 7p15.2 also marked 1 of 16 reported genome-wide significant loci associated with waist-to-hip ratio adjusted for BMI (WHRadjBMI) in an independent GWAS meta-analysis by the GIANT Consortium involving 77 167 individuals of European ancestry with replication in a further 113 636 individuals (rs1055144: discovery *P* = 1.5 × 10^−8^; meta-analysis *P* = 1.0 × 10^−24^; *r*^2^ = 0.5 with rs12700667 in 1000G pilot CEU data) ([@DDU516C6],[@DDU516C7]). This was surprising, as prospective epidemiological studies have suggested consistently that reduced BMI---a measure of overall adiposity---is associated with increased risk of endometriosis, but there is relatively limited evidence for an association with WHRadjBMI---a measure of fat distribution ([@DDU516C8],[@DDU516C9]). We conducted a logistic regression analysis in the IEC dataset of rs1055144 on endometriosis disease status, conditioning on rs12700667, which demonstrated that the SNPs reflected the same association signal (unpublished data; conditional *P* = 0.65).

The epidemiological evidence of an association between endometriosis and BMI, together with the observed GWAS locus in common between endometriosis and WHRadjBMI, led us to conduct a systematic investigation of overlap in association signals between the IEC endometriosis GWAS and GIANT Consortium WHRadjBMI (*N* = 77 167) ([@DDU516C6],[@DDU516C7]) and BMI (*N* = 123 865) ([@DDU516C7],[@DDU516C10]) meta-GWAS datasets through genetic enrichment analyses.

RESULTS {#s2}
=======

Genetic enrichment analysis of endometriosis with overall adiposity and fat distribution {#s2a}
----------------------------------------------------------------------------------------

Using independent, imputed (1000 Genomes pilot reference panel) GWAS datasets of endometriosis (IEC; 3194 cases including 1364 Stage B cases, 7060 controls), BMI (GIANT; 123 865 individuals) and WHRadjBMI (GIANT: 77 167 individuals), we first considered loci genome-wide significantly associated with endometriosis, BMI or WHRadjBMI in each of the individual GWAS. The two genome-wide significant endometriosis loci (intergenic 7p15.2 and *WNT4*) had significantly lower *P*-values of association than expected by chance in the WHRadjBMI GWAS (Table [1](#DDU516TB1){ref-type="table"}: rs12700667, *P* = 4.4 × 10^−5^ and rs7521902, *P* = 1.3 × 10^−3^; binomial *P* = 1.0 × 10^−4^), while 2 of the 16 genome-wide significant WHRadjBMI loci (intergenic 7p15.2 and *GRB14*) had *P* \< 0.01 in the endometriosis GWAS (binomial *P* = 0.011). No enrichment between genome-wide significantly associated loci was observed for endometriosis versus BMI ([Supplementary Material, Table S1](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1): rs12700667, *P* = 0.27 and rs7521902, *P* = 0.92). Table 1.Association results of published IEC genome-wide significant endometriosis loci ([@DDU516C3]) in the GIANT WHRadjBMI GWAS, and of WHRadjBMI loci ([@DDU516C6],[@DDU516C7]) in endometriosis GWAS (lookup results are shown in bold)GWASSNP (proxy; *r*^2^)ChLocation (B36)RAF (allele)StatusEndometriosis all casesEndometriosis Stage B onlyOverall WHRadjBMIFemale-limited WHRadjBMINearest gene*P*-value^c^OR (95% CI)*P*-value^c^OR (95% CI)*P*-value^d^Effect (SE)*P*-value^e^Effect (SE)Endometriosisrs12700667725 868 1640.74 (A)G5.1 × 10^−7^1.21 (1.12--1.31)3.3 × 10^−8^1.36 (1.23--1.50)**4.4 × 10^−5^**−**0.023 (0.005)3.3 × 10^−8^**−**0.023 (0.005)**IntergenicEndometriosisrs7521902122 363 3110.25 (A)G8.9 × 10^−5^1.16 (1.08--1.25)7.5 × 10^−5^1.26 (1.14--1.39)**1.3 × 10^−3^**−**0.020 (0.006)6.1 × 10^−3^**−**0.023 (0.009)***WNT4*WHRadjBMIrs1055144^a^725 837 6340.19 (T)G**3.7 × 10^−5^0.84 (0.77--0.91)**3.1 × 10^−4^0.78 (0.70--0.88)1.5 × 10^−8^0.034 (0.006)2.3 × 10^−6^0.039 (0.008)IntergenicWHRadjBMIrs101952522165 221 3370.41 (C)G**9.8 × 10^−3^0.92 (0.85--0.98)**0.560.92 (0.84--1.00)3.2 × 10^−10^−0.031 (0.005)6.3 × 10^−15^−0.053 (0.007)*GRB14*Female WHRadjBMIrs4684854312 463 8820.43 (C)I (0.98)**0.071.06 (0.99--1.14)**0.141.07 (0.98--1.17)1.0 × 10^−4^0.019 (0.005)2.3 × 10^−8^0.039 (0.007)*PPARG*WHRadjBMIrs7183141226 344 5500.24 (G)G**0.111.06 (0.99--1.15)**0.0541.10 (0.99--1.22)2.4 × 10^−8^0.031 (0.005)8.2 × 10^−10^0.047 (0.008)*ITPR2-SSPN*WHRadjBMIrs68616815173 362 4580.32 (A)I (0.96)**0.150.95 (0.86--1.04)**0.110.93 (0.85--1.00)1.4 × 10^−6^0.026 (0.005)2.1 × 10^−4^0.027 (0.007)*CPEB4*WHRadjBMIrs6795735364 680 4050.41 (T)G**0.211.04 (0.98--1.12)**0.321.04 (0.96--1.14)2.5 × 10^−7^−0.025 (0.005)7.8 × 10^−7^−0.033 (0.007)*ADAMTS9*WHRadjBMIrs2820446\
(rs4846567, *r*^2^ = 1)^b^121 974 8810.71 (C)I (0.99)**0.311.04 (0.97--1.12)**0.221.06 (0.97--1.17)5.1 × 10^−12^0.037 (0.005)8.5 × 10^−18^0.064 (0.007)*LYPLAL1*WHRadjBMIrs498778\
(rs6784615, *r*^2^ = 1)^b^352 453 8930.93 (T)I (0.95)**0.321.08 (0.93--1.24)**0.251.06 (0.89--1.27)4.6 × 10^−5^0.055 (0.010)1.1 × 10^−3^0.063 (0.019)*NISCH-STAB1*WHRadjBMIrs129442166 743 1490.39 (T)I (0.96)**0.371.03 (0.94--1.10)**0.281.03 (0.94--1.13)6.3 × 10^−9^−0.029 (0.005)3.4 × 10^−8^−0.038 (0.007)*LY86*WHRadjBMIrs94916966127 452 6390.51 (C)I (0.99)**0.430.97 (0.91--1.03)**0.640.98 (0.90--1.06)2.1 × 10^−14^−0.037 (0.005)3.4 × 10^−8^−0.038 (0.007)*RSPO3*WHRadjBMIrs14435121252 628 9510.22 (A)G**0.621.02 (0.94--1.10)**0.630.97 (0.88--1.08)3.3 × 10^−8^0.031 (0.005)1.4 × 10^−9^0.048 (0.008)*HOXC13*WHRadjBMIrs9842221119 305 3660.39 (C)I (0.99)**0.690.99 (0.93--1.05)**0.310.95 (0.87--1.04)3.8 × 10^−14^−0.037 (0.005)1.2 × 10^−7^−0.036 (0.007)*TBX15-WARS2*WHRadjBMIrs48230062229 451 6710.57 (A)I (0.97)**0.721.01 (0.95--1.08)**0.821.01 (0.92--1.11)4.7 × 10^−10^0.030 (0.005)6.9 × 10^−8^0.037 (0.007)*ZNRF3*Female WHRadjBMIrs104784245118 816 6190.79 (A)I (0.97)**0.801.01 (0.93--1.10)**0.561.03 (0.93--1.15)1.6 × 10^−4^0.023 (0.006)1.0 × 10^−5^0.037 (0.009)*HSD17B4*WHRadjBMIrs10117311170 613 1710.44 (G)G**0.810.99 (0.93--1.05)**0.771.01 (0.93--1.11)1.7 × 10^−10^0.031 (0.005)2.1 × 10^−5^0.028 (0.007)*DNM3-PIGC*WHRadjBMIrs6905288643 866 8510.56 (A)I (0.80)**0.660.98 (0.91--1.05)**0.660.99 (0.90--1.08)4.2 × 10^−10^0.033 (0.005)7.7 × 10^−13^0.052 (0.007)*VEGFA*[^2][^3][^4][^5][^6]

To investigate whether statistical enrichment extended beyond genome-wide significant loci, we investigated the most significant (*P* \< 1 × 10^−3^) independent (*r*^2^ \< 0.2) endometriosis GWAS signals for enrichment of WHRadjBMI or BMI signals with *P* \< 0.05 and vice versa (number of lookup SNPs per dataset: *n* = 717 to 748; see [Supplementary Material, Methods](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)). We observed statistically significant enrichment between variants associated with endometriosis (particularly Stage B) and WHRadjBMI (all endometriosis versus WHRadjBMI: *P* = 3.7 × 10^−3^; Stage B endometriosis versus WHRadjBMI: *P* = 4.5 × 10^−4^), but not between endometriosis and BMI (all endometriosis versus BMI: *P* = 0.79; Stage B endometriosis versus BMI: *P* = 0.85) (Fig. [1](#DDU516F1){ref-type="fig"}; [Supplementary Material, Table S2](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)). Results were similar when using female-limited WHRadjBMI (*N* = 42 969 women) and BMI (*N* = 73 137 women) GWAS summary statistics ([@DDU516C7]); to optimize power, in the remainder of the paper we therefore focus on sex-combined WHRadjBMI and BMI datasets ([Supplementary Material, Fig. S1](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)). Empirical testing of statistical enrichment through permutation (see [Supplementary Material, Methods](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)) provided near-identical results (Fig. [1](#DDU516F1){ref-type="fig"}; [Supplementary Material, Fig. S1](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)). Figure 1.Genetic enrichment analyses between endometriosis, BMI and WHRadjBMI GWAS datasets, using independent (*r*^2^ \< 0.2) SNPs. The panels show (i) The proportion of SNPs nominally associated (*P* \< 0.05) with WHRadjBMI (**A**) or BMI (**B**) by significance of overall and Stage B endometriosis association (*P* \< 1.0 × 10^−3^ versus *P* ≥ 1 × 10^−3^); (ii) The proportion of SNPs nominally associated (*P* \< 0.05) with overall and Stage B endometriosis by significance of WHRadjBMI (C) and BMI (D) association (*P* \< 1.0 × 10^−3^ versus *P* ≥ 1 × 10^−3^). *P*-values of *χ*^2^ tests assessing statistical difference between proportions are shown above each set of bars, and 95% confidence intervals of the proportions are given on each bar. For differences with *P*~chisq~ \< 0.2, empirical *P*-values are given in brackets (see [Supplementary Material, Methods](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)).

The choice of significance thresholds in the discovery and lookup datasets was based on a balance between applying a sufficiently stringent significance threshold in the discovery dataset that would minimize the proportion of false-positive association signals, while still having sufficient numbers of loci in each of the phenotypic association strata to investigate statistical enrichment, and allow the pursuit of meaningful biological pathway analyses subsequently. We considered the effect of different significance thresholds, for both discovery and lookup, which confirmed results showing enrichment of association signals between endometriosis and WHRadjBMI ([Supplementary Material, Table S3](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)), but no enrichment between endometriosis and BMI ([Supplementary Material, Table S4](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)).

To investigate potential genome-wide sharing of loci between endometriosis and WHRadjBMI or BMI, we performed polygenic prediction analyses ([@DDU516C11]) evaluating whether the aggregate effect of many variants of small effect in the WHRadjBMI and BMI GWAS could predict endometriosis status in the IEC GWAS (see [Supplementary Material, Methods](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)). There was no significant association between the WHRadjBMI- or BMI-derived profile scores (overall or female limited) and all/Stage B endometriosis ([Supplementary Material, Tables S5--S8](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)), suggesting no evidence for a directionally consistent *en masse*, genome-wide, shared common genetic component.

We next investigated the variants with most significant evidence for association with both endometriosis (*P* \< 1 × 10^−3^) and WHRadjBMI (*P* \< 0.05) for predominance in direction of phenotypic effects ([Supplementary Material, Tables S9 and S10](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1) [and Fig. S2](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)). No statistically significant directional consistency was observed for these variants (*P* \> 0.47), nor for the 17 loci (Table [1](#DDU516TB1){ref-type="table"}) that were genome-wide significantly associated with either trait (Fig. [2](#DDU516F2){ref-type="fig"}, *P* \> 0.44). Intergenic 7p15.2 and *WNT4* showed discordant directions of effect, while the effect of *GRB14* was concordant (Fig. [2](#DDU516F2){ref-type="fig"}). This could suggest the presence of multiple biological pathways through which the variants influence the two phenotypes. We next set out to investigate the common biology suggested by genetic variants associated with both endometriosis and WHRadjBMI. Figure 2.Directions of effect of 17 independent SNPs genome-wide significantly associated with all (**A**) or Stage B (**B**) endometriosis, or WHRadjBMI. Intergenic 7p15.2, *WNT4*, and *GRB14* are shown in red. Linear regression *R*^2^ and *P*-values used to test for significant directionality of effects ([@DDU516C35]) are shown.

Biology of the loci shared between endometriosis and fat distribution {#s2b}
---------------------------------------------------------------------

Our analysis showing significant enrichment between SNPs associated with all or Stage B endometriosis (*P* \< 1 × 10^−3^) and WHRadjBMI (*P* \< 0.05) shown in Figure [1](#DDU516F1){ref-type="fig"} involved 1284 independent (*r*^2^ \> 0.2) loci. We explored the biological function of the loci most strongly associated with WHRadjBMI, at nominal *P* \< 0.005 (*n* = 16, Table [2](#DDU516TB2){ref-type="table"}; see [Supplementary Material, Tables S11 and S12](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1) for all variants associated at *P* \< 0.05). Two novel loci, rs560584 near *KIFAP3* (all endometriosis) and rs11619804 in *CAB39L* (Stage B endometriosis), were significantly associated with WHRadjBMI after Bonferroni correction allowing for 1284 independent tests (*P* \< 3.89 × 10^−5^). Table 2.Results of the top all/Stage B endometriosis loci (*P* \< 1 × 10^−3^) associated with WHRadjBMI at *P* \< 0.005SNPChrPosition (B36)RAF (allele)EndometriosisOverall WHRadjBMIFemale-limited WHRadjBMINearest loci*P*-valueOR (95% CI)*P*-valueEffectSE*P*-valueEffectSE(distance)All cases rs5605841168 357 1360.41 (T)1.4 × 10^−4^1.14 (1.07--1.22)1.4 × 10^−5^−0.0210.0051.1 × 10^−3^−0.0220.677*KIFAP3* (46 632) rs12700667725 868 1640.74 (A)5.1 × 10^−7^1.22 (1.13--1.32)4.4 × 10^−5^−0.0230.0053.4 × 10^−4^−0.0280.284*NFE2L3* (2 90 221) rs2921188312 387 1150.64 (A)5.9 × 10^−4^1.13 (1.05--1.21)1.1 × 10^−3^0.0170.0051.8 × 10^−4^0.0260.054*PPARG* (0) rs12502482215 995 3380.27 (A)1.6 × 10^−5^1.17 (1.09--1.26)1.0 × 10^−3^0.0180.0059.9 × 10^−4^0.0250.242*FN1* (0) rs2630787321 847 3390.52 (C)9.2 × 10^−4^1.12 (1.05--1.19)1.9 × 10^−3^−0.0150.0040.38−0.0060.030*ZNF659* (79 518) rs1430788267 721 9160.31 (C)9.3 × 10^−5^1.15 (1.07--1.23)2.7 × 10^−3^0.0160.0053.1 × 10^−3^0.0220.330*ETAA1* (230 878) rs9067213184 687 6910.41 (A)6.1 × 10^−5^1.16 (1.08--1.24)4.2 × 10^−3^0.0150.0051.7 × 10^−3^0.0230.140*KLHL6* (322) rs18688944187 606 7280.80 (C)2.3 × 10^−4^1.16 (1.07--1.26)4.9 × 10^−3^−0.0180.0060.13−0.0130.524*MTNR1A* (85 075) rs3820282122 340 8020.16 (T)3.3 × 10^−7^1.26 (1.15--1.37)5.0 × 10^−3^−0.0190.0070.09−0.0160.749*WNT4* (0)Stage B cases rs116198041349 888 1310.53 (C)4.8 × 10^−4^1.17 (1.07--1.28)1.1 × 10^−5^0.0220.0052.2 × 10^−2^0.0160.022*CAB39L* (0) rs12700667725 868 1640.74 (A)3.3 × 10^−9^1.36 (1.23--1.50)4.4 × 10^−5^−0.0230.0053.4 × 10^−4^−0.0280.284*NFE2L3* (290 221) rs2782659645 794 7680.33 (G)4.2 × 10^−4^1.18 (1.08--1.30)9.2 × 10^−5^0.0200.0051.7 × 10^−4^0.0270.108*RUNX2* (167 970) rs65563015176 460 1830.63 (G)7.4 × 10^−4^1.17 (1.07--1.28)1.9 × 10^−4^−0.0210.0057.8 × 10^−3^−0.0210.845*FGFR4* (2450) rs12502482215 995 3380.27 (A)2.9 × 10^−8^1.32 (1.19--1.45)1.2 × 10^−3^0.0180.0059.9 × 10^−4^0.0250.242*FN1* (0) rs41318161161 662 6480.85 (T)5.4 × 10^−4^1.24 (1.10--1.41)1.5 × 10^−3^0.0220.0070.250.0110.072*NUF2* (70 470) rs99123351777 552 9480.69 (T)3.1 × 10^−4^1.19 (1.08--1.31)3.5 × 10^−3^−0.0210.0070.10−0.0160.454*ASPSCR1* (0) rs108783621264 703 7600.69 (C)4.9 × 10^−4^1.19 (1.08--1.31)3.6 × 10^−3^0.0150.0053.1 × 10^−3^0.0220.204*HMGA2* (57 421) rs2807357122 364 5710.64 (A)9.7 × 10^−4^1.16 (1.06--1.27)3.7 × 10^−3^−0.0150.0051.0 × 10^−3^−0.0240.081*WNT4* (22 373) rs9067213184 687 6910.41 (A)1.4 × 10^−4^1.20 (1.09--1.32)4.2 × 10^−3^0.0150.0051.7 × 10^−3^0.0230.140*KLHL6* (322) rs12267660104 419 5300.85 (G)7.9 × 10^−4^1.24 (1.09--1.40)4.6 × 10^−3^0.020.0078.0 × 10^−3^0.0300.133*CR749391* (191 913) rs11685481267 590 2530.15 (C)8.4 × 10^−4^1.23 (1.09--1.38)4.8 × 10^−3^0.0180.0061.1 × 10^−2^0.0220.451*ETAA1* (99 215)

The endometriosis risk allele T of rs560584 (OR = 1.14 (1.07--1.22), *P* = 1.42 × 10^−4^) was associated with lower WHRadjBMI (*β* = −0.021, *P* = 1.47 × 10^−5^), and located in an intergenic region 46 kb downstream of *KIFAP3* (*Kinesin-associated protein 3*). Together with *KIF3A* and *KIF3B*, *KIFAP3* forms a kinesin motor complex, KIF3, that mediates cellular transport of N-cadherin and β-catenins ([@DDU516C12]), which are involved in cell adhesion, the *Wnt* canonical pathway and cell cycle progression ([@DDU516C13]). The *Wnt/β*-catenin signalling pathway acts as a molecular switch for adipogenesis ([@DDU516C14]) and has multiple suggested roles in endometriosis through sex hormone homeostasis regulation ([@DDU516C15]), its role in development of female reproductive organs ([@DDU516C16]), molecular mechanisms of infertility ([@DDU516C17]) and mediation of fibrogenesis ([@DDU516C18]).

The Stage B endometriosis risk allele C of rs11619804 (OR = 1.17 (1.07--1.28); *P* = 4.88 × 10^−4^), located in *CAB39L* (Calcium-Binding Protein 39-Like), was associated with increased WHRadjBMI (*β* = 0.022, *P* = 1.06 × 10^−5^; Table [2](#DDU516TB2){ref-type="table"}). The function of this gene is not well characterized but the encoded protein interacts with a serine threonine kinase (*STK11*) that functions as a tumour suppressor ([@DDU516C19]).

Rs12700667 in the intergenic region 7p15.2 remained among the strongest associated shared signals, with the endometriosis risk allele A associated with reduced WHRadjBMI (*β* = −0.023, *P* = 4.4 × 10^−5^). The association maps to an intergenic high LD region of 48 kb (*r*^2^ \> 0.8) of unknown functionality. Further interesting nearby loci include the miRNA *hsa-mir-148a*, with a purported role in *Wnt/β*-catenin signalling ([@DDU516C14]); *NFE2L3* (nuclear factor (erythroid-derived 2)-like 3), a transcription factor suggested to be involved in cell differentiation, inflammation and carcinogenesis ([@DDU516C20]). The *WNT* signalling pathway was further highlighted by the nominal association of two independent (*r*^2^ = 0.06) endometriosis risk variants near *WNT4* (wingless-type MMTV integration site family), rs3820282 (genic) and rs2807357 (22.4 kb downstream), with reduced WHRadjBMI (*β* = −0.019, *P* = 5.0 × 10^−3^; *β* = −0.015, *P* = 3.7 × 10^−3^; Table [2](#DDU516TB2){ref-type="table"}). Of note is that all shared variants implicated in *WNT* signalling (in/near intergenic 7p15.2, *WNT4*, *KIFAP3*) showed consistent---discordant---phenotypic directions of effect.

Risk variant rs10195252, 34.6 kb downstream of *GRB14* (growth factor receptor-bound protein 14) was the third locus with significant evidence for association with both overall (not Stage B) endometriosis and WHRadjBMI (Table [1](#DDU516TB1){ref-type="table"}). *GRB14* has an inhibitory effect on insulin receptor signalling ([@DDU516C21]), may have a role in signalling pathways that regulate growth and metabolism and has been shown to interact with fibroblast growth factor receptors ([@DDU516C22]). This shared variant is also in high LD (*r*^2^ = 0.93 and = 0.87, respectively) with a type 2 diabetes risk variant rs13389219 ([@DDU516C23]) and fasting insulin risk variant rs6717858 ([@DDU516C24]).

Other loci of interest include rs2921188 in *PPARG* and rs6556301 near *FGFR4* (Table [2](#DDU516TB2){ref-type="table"})*.* The endometriosis risk allele A of rs2921188 (OR = 1.13, 95% CI: 1.05--1.21), *P* = 5.9 × 10^−4^) in *PPARG* (peroxisome proliferator-activated receptor gamma) is associated with increased WHRadjBMI (*β* = 0.017; *P* = 1.1 × 10^−3^). *PPARG* is a nuclear hormone receptor that regulates fatty acid storage and glucose metabolism. Synthetic ligands, such as insulin sensitizing drugs, target *PPARG* in treatment of diabetes to lower serum glucose levels ([@DDU516C25]) and are also documented to have anti-inflammatory, anti-angiogenic and anti-proliferative effects on endometrium, with baboon models suggesting a role in targeting endometriotic disease ([@DDU516C26]). Stage B endometriosis risk allele G of rs6556301 near *FGFR4* (*fibroblast growth factor receptor*, OR = 1.17 \[1.07--1.28\], *P* = 7.4 × 10^−4^) is associated with reduced WHRadjBMI (*β* = −0.021, *P* = 1.9 × 10^−4^). *FGFR4* interacts with fibroblast growth factors, which have roles in angiogenesis, wound healing and cell migration ([@DDU516C27]).

Expression quantitative trait loci analysis of the shared endometriosis and fat distribution loci {#s2c}
-------------------------------------------------------------------------------------------------

We investigated the potential impact of the described 16 genes (Table [2](#DDU516TB2){ref-type="table"}) shared between endometriosis and WHRadjBMI on transcriptional function using three public expression data resources: (i) the Mammalian Gene Expression Uterus database (MGEx-Udb) ([@DDU516C28]) containing published information on transcriptional activity of specific genes in human endometrial tissue from individuals with and without endometriosis; (ii) the MuTHER study which collected expression and eQTL data from 776 abdominal fat tissues ([@DDU516C29]); and (iii) the MOLOBB dataset of differential expression levels between abdominal and gluteal fat from 49 individuals ([@DDU516C30]). Based on the limited available evidence in the MGEx-Udb database, two genes are transcribed in endometrial tissue of women with endometriosis but dormant in those without endometriosis: *PPARG* and *FGFR4* ([Supplementary Material, Table S13](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)). Of the 16 genes, 15 had probes present within 1 Mb either side of the SNP in the MuTHER database; however, none showed significant association with nearby transcripts in abdominal fat tissue ([Supplementary Material, Table S14](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)). The MOLOBB study data showed *cis*-eQTL evidence for differential expression of two genes; *KIFAP3* (rs560584; fold change = 0.14, adjusted *P* = 0.04) ([Supplementary Material, Table S15](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)). Additional transcriptional evidence relevant to the intergenic 7p15.2 locus includes the presence of an expression QTL associated with a transcript of unknown function, *AA553656*, in subcutaneous abdominal fat tissue ([@DDU516C6]), and the differential expression of nearby *hsa-miR-148a* between gluteal and abdominal fat tissue samples ([@DDU516C31]).

Pathway analysis {#s2d}
----------------

To identify potential common biological pathways involved in the aetiology of endometriosis and the variability of fat distribution, we conducted pathway analyses using genes with evidence for enrichment between the traits using (i) the PANTHER database ([@DDU516C32]) and (ii) GRAIL ([@DDU516C33]). For the PANTHER analysis, we selected the 91 and 108 genes located in a 1 Mb interval surrounding each independent SNP associated with all endometriosis (*P* \< 1.0 × 10^−3^) and WHRadjBMI (*P* \< 0.05), and Stage B endometriosis (*P* \< 1.0 × 10^−3^) and WHRadjBMI (*P* \< 0.05), respectively (see [Supplementary Material, Methods](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)). This excluded intergenic loci without a gene within 1 Mb, such as our top shared locus at 7p15.2. We tested whether the two sets of genes showed significant overrepresentation of a particular pathway, for each of 176 curated pathways and 241 biological processes. The top enriched pathways were 'developmental processes' (all endometriosis: *P* = 1.2 × 10^−5^; Stage B: *P* = 1.25 × 10^−4^), '*WNT* signalling' (all endometriosis: *P* = 1.07 × 10^−4^), 'gonadotropin-releasing hormone receptor' (all endometriosis: *P* = 1.48 × 10^−3^), 'cadherin signalling' (Stage B: *P* = 6.42 × 10^−4^), 'FGF signalling' (Stage B: *P* = 2.96 × 10^−3^) and 'TGF-beta signalling' (Stage B: *P* = 1.48 × 10^−3^) pathways ([Supplementary Material, Tables S16 and S17](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)). Bonferroni correction for the number of pathways tested (see [Supplementary Material, Methods](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)) rendered '*WNT* signalling', 'developmental processes', 'cellular processes' and 'cell communication' significantly enriched; however, this adjustment is conservative, as exemplified by 'cadherin signalling' genes being a subset of those in the '*WNT* signalling' pathway. Sensitivity analyses exploring the effect of different endometriosis association thresholds on pathway analyses showed very consistent results for threshold *P* \< 1.0 × 10^−2^, with the same top three enriched pathways---*WNT* signalling, Cadherin signalling and Gonadotropin-releasing hormone receptor pathway. No meaningful pathway analyses could be conducted on the limited number of genes passing association threshold *P* \< 1 × 10^−4^ ([Supplementary Material, Table S18](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)).

We used GRAIL ([@DDU516C33]) to search for connectivity between the 91 and 108 genes all/Stage B endometriosis and WHRadjBMI-associated genes and specific keywords from the published literature that describe potential functional connections. We identified 17 genes with nominal significance (*P* \< 0.05) for potential functional connectivity for 'all' endometriosis and WHRadjBMI and six genes for Stage B endometriosis and WHRadjBMI ([Supplementary Material, Fig. S3](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1) [ and Tables S19 and S20](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)). The keywords associated with these connections included 'cadherin', 'differentiation', 'development' and 'insulin' for 'all' endo, and 'development' and 'embryos' for Stage B endometriosis, marking again developmental processes and cadherin signalling as biological pathways shared in the origins of endometriosis and fat distribution.

DISCUSSION {#s3}
==========

In this study, we have investigated the overlap in genetic association signals from the largest GWA studies to date of endometriosis, overall adiposity (BMI) and fat distribution (WHRadjBMI). Our results demonstrated that there is a shared genetic basis between endometriosis and fat distribution that extends over and above the single genome-wide significant locus that has been reported in GWAS of the separate traits. Our analyses highlight novel loci in/near *KIFAP3* and *CAB39L*, which together with intergenic 7p15.2, *WNT4* and *GRB14*, showed significant evidence of trait association sharing. The strength of evidence of enrichment was similar for overall versus female-limited WHRadjBMI loci, which may be unexpected, given that endometriosis is a female condition. However, the lack of a stronger enrichment between female-specific WHRadjBMI GWAS results and endometriosis, compared with all WHRadjBMI results should be considered against the effects of a reduced sample size used for female-specific WHRadjBMI analyses on power of association detection.

The enrichment of associated variants was generally stronger when the endometriosis cases were restricted to moderate--severe (Stage B) disease, despite the smaller sample size. Indeed, the association of the top intergenic GWAS locus on 7p15.2, also genome-wide significantly associated with WHRadjBMI, is limited to Stage B endometriosis. Stage B---or ASRM Stages III/IV disease ([@DDU516C34])---is typically characterized by ovarian (endometrioma) or deep infiltrating (rectovaginal) lesions, which were shown to have a substantially greater underlying genetic contribution than milder, peritoneal disease (ASRM Stage I/II) ([@DDU516C3]). The particular enrichment between WHRadjBMI and Stages III/IV endometriosis is intriguing, and another reason for further functional work to concentrate on this endometriosis sub-type. There are, however, specific loci that show enrichment of association with WHRadjBMI and overall endometriosis, the analysis of which therefore remains of interest. An example is *GRB14*, which did not show significant association with Stage B disease, displayed a concordant direction of effect between endometriosis and WHRadjBMI, and the biological function of which also seems to suggest an entirely different contribution to the origins of both phenotypes than the 7p15.2 and *WNT4* loci.

The limited available eQTL data showed significant evidence for differential expression of *KIFAP3* between different fat depots. The variants with most evidence for enrichment between the traits, in/near intergenic 7p15.2, *KIFAP3* and *WNT4*, were all implicated in *WNT* signalling and had consistent---discordant---directions of effect, with endometriosis risk alleles associated with a decreased WHRadjBMI. Indeed, biological pathway analyses showed significant evidence for the involvement of developmental processes and *WNT* signalling in endometriosis aetiology and regulation of fat distribution, a potential pleiotropic connection that has not been reported to date.

The relatively limited epidemiological evidence of phenotypic correlation between endometriosis and WHRadjBMI ([@DDU516C8],[@DDU516C9]) is consistent with the absence of strong directional consistency of phenotypic effects of genetic variants underlying both traits at a genome-wide level. Most studies of genetic pleiotropy between traits to date have focused on genome-wide directional consistency between epidemiologically or clinically (postulated) correlated traits, such as different metabolic traits ([@DDU516C6],[@DDU516C35]) or psychiatric conditions ([@DDU516C36]). However, genome-wide consistency in directionality of phenotypic effects would most likely apply to traits that share a large proportion of causality, and that epidemiologically lie on the same causal pathway(s) and are thus more likely to be examples of mediated (genetic variants influencing one phenotype indirectly through association with a second phenotype) rather than biological (genetic variants exerting a direct biological influence on more than one phenotype) pleiotropy ([@DDU516C37]). Thus, our results of genetic enrichment between endometriosis and WHRadjBMI demonstrate an example of the biological complexity of aetiological associations between complex traits, and suggest that the underlying shared loci are potentially biologically pleiotropic, given the absence of phenotypic correlation between endometriosis and WHRadjBMI and absence of *en masse* directional consistency of shared genetic variants on the phenotypes ([@DDU516C37],[@DDU516C38]). It also demonstrates more generally how potential perturbation of a causal pathway through, for example, drug treatment targeting one trait could have unexpected effects on another, even when there is no clear evidence that these traits are associated clinically or epidemiologically---a problem often encountered in drug development. Systematic exploration of biological pleiotropy of genetic variants marking potential drug targets may help in highlighting the potential of such unwanted or unexpected effects.

While the observed genetic enrichment between endometriosis and WHRadjBMI presents new avenues for exploring common biology, the total absence of any genetic enrichment between endometriosis and BMI (within the limits of power presented by these large datasets) is intriguing given the consistent, prospective, observational epidemiological evidence of phenotypic association between reduced BMI and endometriosis risk ([@DDU516C8]). Our analyses represent an adaptation of Mendelian randomization analyses ([@DDU516C39],[@DDU516C40]), in which genetic variants robustly associated with BMI in the largest GWAS analyses to date ([@DDU516C10]) are investigated for association with endometriosis. The total lack of genetic enrichment suggests that reduced BMI is not causally related to endometriosis risk. Rather, it suggests that the observed phenotypic association ([@DDU516C8]) is either driven by shared environmental factors, or is due to confounding factors related to BMI affecting, for example, diagnostic opportunity for endometriosis.

These novel findings present an entirely new opportunity for functional targeted follow-up of pleiotropic loci between endometriosis and WHRadjBMI in relevant disease tissues such as endometrium and fat tissue, cellular systems, animal models and further cross-trait comparisons, to uncover their biological functions and to assess how studies in the fat distribution research field can inform research into endometriosis pathogenesis, biomarker identification and drug target discovery and validation.

MATERIALS AND METHODS {#s4}
=====================

Genome-wide association studies {#s4a}
-------------------------------

### IEC endometriosis GWAS {#s4a1}

This GWAS included 3194 surgically confirmed endometriosis cases and 7060 controls from Australia and the UK. Disease severity of the endometriosis cases was assessed retrospectively from surgical records using the rAFS classification system and grouped into two phenotypes: Stage A (Stage I or II disease or some ovarian disease with a few adhesions; *n* = 1686) or Stage B (Stage III or IV disease; *n* = 1364). We previously showed an increased genetic loading among 1364 cases with Stage B endometriosis compared with 1666 with Stage A disease ([@DDU516C3]), which led to two GWA analyses, including (i) 3194 'all' endometriosis case and (ii) 1364 Stage B cases (Table [3](#DDU516TB3){ref-type="table"}). The genotyped data were imputed up to 1000 Genomes pilot reference panel (B36, June 2010) and the GWAS was performed again, using a missing data likelihood in a logistic regression model including a covariate representing the Australian and the UK strata, with the imputed data (*N* = 12.5 million SNPs). The enrichment analysis we present is from this set of results. Table 3.Summary description of the GWAS used in the genetic enrichment analysisGWASConsortiumSample sizeNo. of SNPs (million)ReferencesEndometriosis---all casesIEC3194 cases, 7060 controls∼12.5Painter *et al*. ([@DDU516C3])Endometriosis---Stage B casesIEC1363 cases, 7060 controls∼12.5Painter *et al*. ([@DDU516C3])WHRadjBMIGIANT77 167∼2.85Heid *et al*. ([@DDU516C6])Female-limited WHRadjBMIGIANT42 969∼2.85Randall *et al*. ([@DDU516C7])BMIGIANT123 865∼2.85Speliotes *et al*. ([@DDU516C10])Female-limited BMIGIANT73 137∼2.85Randall *et al*. ([@DDU516C7])[^7]

### GIANT Consortium {#s4a2}

#### WHR GWAS {#s4a2a}

A total of 77 167 subjects of European ancestry informative of body fat distribution measurement WHR from 32 GWAS were included ([@DDU516C6]). The genotype data were imputed up to HapMap 2 CEU reference panel. The associations of 2.85 million SNPs with WHR were examined in a fixed-effects meta-analysis, after inverse normal transformation of WHR and adjusting for BMI and age within each study in an additive genetic model; analyses were conducted for males and females combined ([@DDU516C6]) and limited to females only ([@DDU516C7]) (Table [3](#DDU516TB3){ref-type="table"}).

#### BMI GWAS {#s4a2b}

A total of 123 865 subjects with overall adiposity measurement BMI from 46 GWAS were included ([@DDU516C10]). The genotype data were imputed up to HapMap two CEU reference panels. The associations of 2.85 million SNPs with BMI were tested in an inverse-variance meta-analysis, after inverse normally transformation of BMI and adjusting for age and other appropriate covariates in an additive genetic model within each study; analyses were conducted for males and females combined ([@DDU516C10]) and limited to females only ([@DDU516C7]) (Table [3](#DDU516TB3){ref-type="table"}).

Genetic enrichment analysis {#s4b}
---------------------------

With one test of association conducted for each SNP, the GWAS analyses produced a genome-wide distribution of *P*-values of individual SNP associations. Prior to testing enrichment: (i) the overlap of SNPs present in endometriosis GWAS versus WHRadjBMI and BMI GWAS was taken, (ii) all SNPs with MAF ≤ 0.01 were removed, (iii) all SNPs with A/T and C/G base pairs were removed, (iv) correlated SNPs (*r*^2^ \> 0.2) were removed as previously reported ([@DDU516C41]) by taking the most significantly associated SNP and eliminating all SNPs that have a HapMap CEU pairwise correlation coefficient (*r*^2^) \> 0.2 with that SNP, then processing to the next strongly associated SNP remaining. This resulted in 173 157 independent SNPs in endometriosis versus WHRadjBMI and 173 223 in endometriosis versus BMI enrichment analyses.

The independent SNPs in the tails (*P* \< 1 × 10^−3^) of the association results distribution of the two endometriosis GWAS (all endometriosis and 'Stage B' cases) were investigated for enrichment of WHRadjBMI or BMI low *P*-value (*P* \< 0.05) association signals; in reversal, SNPs in the tails of WHRadjBMI and BMI GWAS (*P* \< 1 × 10^−3^) were investigated for evidence of nominal association (*P* \< 0.05) in the two endometriosis GWAS. The threshold of *P* \< 1 × 10^−3^ corresponded to the point at which endometriosis GWAS results started to deviate from the null distribution (evidence for association) in the overall and Stage B endometriosis Q--Q plots ([Supplementary Material, Fig. S4](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddu516/-/DC1)). Enrichment was assessed in R by means of Pearson\'s *χ*^2^ tests with Yates\' continuity correction, testing for the difference in proportion of SNPs with association *P* \< 0.05 in the lookup dataset according to association in the discovery dataset (*P* \< 1 × 10^−3^ versus *P* ≥ 1 × 10^−3^). To test for consistency in directionality of phenotypic effects of the SNPs with evidence of enrichment, linear regression analysis was performed on the effect (*β*) of each SNP for WHRadjBMI as predictor variable and the effect (*β*) of endometriosis risk as the outcome variable ([@DDU516C35]). In addition, a two-sided binomial test was performed with null hypothesis *P* = 0.50.

Permutation-based enrichment analysis {#s4c}
-------------------------------------

For those results that showed nominally significant (*P* \< 0.10) evidence for enrichment in *χ*^2^ tests of contingency tables, we performed permutation-based analyses to obtain empirical estimates of significance of enrichment. We (i) randomly picked the same number of independent SNPs 'associated' with the discovery trait at *P* \< 1 × 10^−3^ (e.g. the number of SNPs associated with all endometriosis at *P* \< 1 × 10^−3^ was *n* = 717) from the WHRadjBMI dataset; (ii) counted how many of the randomly selected SNPs had *P*-values of association with WHRadjBMI \<0.05; (iii) repeated Steps (i) and (ii) 10 000 times; (iv) determined the number of instances among the 10 000 draws in which the number of SNPs associated at *P* \< 0.05 with WHRadjBMI was greater or equal to the number we observed in our original analysis (e.g. ≥52/717). For example, for overall endometriosis and overall WHRadjBMI, we observed this in 26/10 000 instances, corresponding to a *P*-value of 2.6 × 10^−3^, which was very similar to the *P*-value obtained from the *χ*^2^ test (*P* = 3.7 × 10^−3^).

Polygenic prediction analysis {#s4d}
-----------------------------

The independent SNPs in both WHRadjBMI and endometriosis datasets were used to conduct a polygenic prediction analysis ([@DDU516C11]). The aim of this analysis was to evaluate the aggregate effects of many SNPs of small effect and assess whether subsets of SNPs selected in this manner from one disease/trait GWAS predict disease/trait status in another, thus providing a measure of a common polygenic component with concordant directions of effect underlying the traits. Briefly, subsets of SNPs were selected from the WHRadjBMI GWAS data based on their association with WHRadjBMI using increasingly liberal thresholds, that is, *P* \< 0.01, *P* \< 0.05, *P* \< 0.1, *P* \< 0.2, *P* \< 0.3, *P* \< 0.4, *P* \< 0.5 and *P* \< 0.75. Using these thresholds, we defined sets of allele-specific scores in the WHRadjBMI dataset to generate risk profile scores for individuals in the endometriosis dataset. For each individual in the endometriosis dataset, we calculated the number of score alleles they possessed, each weighted by their effect size (*β*-value) of association in the WHRadjBMI dataset. To assess whether the aggregate scores were associated with endometriosis risk, we tested for a higher mean score in cases compared with controls. Logistic regression was used to assess the relationship between endometriosis disease status and aggregate risk score.

Expression analyses {#s4e}
-------------------

### MGEx-Udb {#s4e1}

The mammalian gene expression uterus database (MGEx-Udb) is a manually curated uterus-specific database created using a meta-analysis approach from published papers ([@DDU516C28]) that provides lists of transcribed and dormant genes for various normal, pathological (e.g. endometriosis, cervical cancer and endometrial cancer) and experimental (e.g. treatment and knockout) conditions. Each gene\'s expression status is indicated by a reliability score, derived based on the consensus across multiple samples and studies which highly variable (<http://resource.ibab.ac.in/MGEx-Udb/>).

### MuTHER {#s4e2}

The MuTHER resource includes LCLs, skin and adipose tissue-derived simultaneously from a subset of well-phenotyped healthy female twins ([@DDU516C29]). Whole-genome expression profiling of the samples, each with either two or three technical replicates, was performed using the Illumina Human HT-12 V3 BeadChips (Illumina, Inc.) according to the protocol supplied by the manufacturer. Log2 transformed expression signals were normalized separately per tissue as follows: quantile normalization was performed across technical replicates of each individual followed by quantile normalization across all individuals.

Genotyping was conducted using a combination of Illumina arrays (HumanHap300, HumanHap610Q, 1M-Duo and 1.2MDuo 1 M). Untyped HapMap2 SNPs were imputed using the IMPUTE software package (v2). In total, there were 776 samples with genotypes and expression values in adipose tissue. Association between all SNPs (MAF \> 5%, IMPUTE info score \> 0.8) within a gene or within 1 Mb of the gene transcription start or end site, and normalized expression values, were performed with the GenABEL/ProbABEL packages ([@DDU516C42]) using polygenic linear models incorporating a kinship matrix (GenABEL) followed by the mm score test with imputed genotypes (ProbABEL). Age and experimental batch were included as cofactors in the analysis. Benjamini Hochberg corrected *P*-values are reported.

### MolOBB {#s4e3}

We performed differential *cis*-eQTL analysis to compare the expression levels in gluteal and abdominal fat tissue from 49 individuals in the MolOBB dataset (24 with and 25 without metabolic syndrome---MetSyn) ([@DDU516C30]). We first checked for the presence of the SNP in the MolOBB genotype data and, in the case of absence, selected any proxies (*r*^2^ \> 0.8) available. We then searched for nearby genes (±500 kb) covered by the expression data using the bioconductor R package GenomicRanges ([@DDU516C43]) and tested for association at each pair using a linear model with the expression level as an outcome and the SNP allelic dosage as a predictor, adjusting for age, gender and MetSyn case--control status. This analysis was carried out for both abdominal and gluteal subcutaneous adipose tissue. To investigate whether genes were differentially expressed between the two tissues, we applied a linear mixed model with tissue, MetSyn case--control status, gender and plate were as fixed effects, and subject as a random effect using MAANOVA ([@DDU516C44]), as previously described in Min *et al*. ([@DDU516C30]). We report the uncorrected and genome-wide FDR corrected *F*s test *P*-values ([@DDU516C30]).

Biological pathway analysis {#s4f}
---------------------------

### PANTHER {#s4f1}

We conducted analyses using the PANTHER 8.1 database containing pathway information on 20 000 genes (*Homo sapiens*) ([@DDU516C32]). We selected independent SNPs, which had association *P*-values \< 1 × 10^−3^ in the endometriosis datasets and an association *P*-value of \<0.05 in the WHRadjBMI dataset, resulting in (i) 91 SNPs for all endometriosis and WHRadjBMI and (ii) 108 SNPs for Stage B endometriosis and WHRadjBMI. Each SNP was mapped to the closest gene within 1 Mb; 88 of 91 and 103 of 108 genes were present in the PANTHER database, and these subsets were tested for correlation with 241 biological processes and 176 pathways classified in the database ([@DDU516C32]). For each biological process/pathway, the difference between the observed fraction of genes in that pathway and the number expected by chance was tested using Fisher exact test. A Bonferroni correction was used as a conservative method for adjusting for the maximum number of biological processes (*n* = 278; *P* = 1.80 × 10^−4^) and pathways (*n* = 78; *P* = 6.41 × 10^−4^) tested.

SUPPLEMENTARY MATERIAL {#s5}
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[^1]: These authors jointly directed this work.

[^2]: Logistic regression analysis in the IEC GWAS shows that rs1055144 marks the same locus as rs12700667 (conditional *P* = 0.65; *r*^2^ = 0.8).

[^3]: SNP was not genotyped in the endometriosis GWAS dataset; result shown is of proxy SNP.

[^4]: Results are based on an updated GWAS performed using genotype data imputed up to 1000 Genomes pilot reference panel (B36, June 2010).

[^5]: Results are from the GIANT WHRadjBMI discovery GWAS dataset (*N* = 77 167); 3 of the 14 WHRadjBMI loci have *P* \> 5.0 × 10^−8^, however, they reached genome-wide significance combined with replication analyses in up to a further 113 636 individuals ([@DDU516C6]).

[^6]: Results from the GIANT WHRadjBMI discovery female-limited GWAS dataset (*N* = 42 969); one of the two female-limited WHRadjBMI loci have *P* \> 5.0 × 10^−8^, however, they reached genome-wide significance combined with replication analyses in up to a further 71 295 individuals ([@DDU516C7]).

[^7]: IEC, International Endogene Consortium; GIANT, Genetic Investigation of Anthropometric Traits Consortium; BMI, body mass index adjusted for age; WHRadjBMI, waist to hip ratio adjusted for BMI and age.
